NCT03712956View on ClinicalTrials.gov

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

PHASE2UnknownINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 25, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Breast Cancer
Interventions
DRUG

Caelyx®

Caelyx® every two weeks for 8 courses

Trial Locations (1)

Unknown

European Institute of Oncology, Milan

Sponsors
All Listed Sponsors
collaborator

Janssen-Cilag International NV

INDUSTRY

lead

European Institute of Oncology

OTHER